Electronic Theses and Dissertation

Kanker ovarium merupakan kanker ginekologi tersering ketiga di Indonesia. Insidensi kanker ovarium di Indonesia tahun 2020 adalah 14.896 kasus baru dan 9.000 kematian. Kemoterapi bertujuan untuk menghentikan pertumbuhan sel kanker. Obat kemoterapi pada kanker ovarium memiliki efek samping mielosupresi akan menekan sel-sel progenitor di sumsum tulang yang mengakibatkan dampak terhadap profil hematologi. Tujuan penelitian ini untuk mengetahui profil hematologi pasien kanker ovarium sebelum dan sesudah kemoterapi siklus ke-2 di RSUDZA Banda Aceh Tahun 2022. Penelitian deskriptif retrospektif ini menggunakan data rekam medik dalam rentang waktu Januari - Desember 2022. Data dianalisis menggunakan tabel distribusi frekuensi dan uji t berpasangan antara sebelum dan sesudah kemoterapi. Data rekam medik yang memenuhi kriteria inklusi dan eksklusi pada penelitian ini berjumlah 65. Hasil penelitian ini menunjukkan mayoritas berusia 46-55 tahun (41,5%), regimen kemoterapi terbanyak carboplatin dan fancopac (78,5%), jenis histopatologi terbanyak Papillary Adenocarcinoma (47,7%), rata-rata hemoglobin sebelum kemoterapi 9,90 (SD ± 3,71) dan sesudah kemoterapi 10,75 g/dL (SD ± 2,70), rata-rata trombosit sebelum kemoterapi 308,37 × 〖10〗^3 mm^(3 ) (SD ± 147,23 ) dan sesudah kemoterapi 311,48 × 〖10〗^(3 /) mm^3(SD ± 109,96), rata-rata leukosit sebelum kemoterapi 6,18 × 〖10〗^(3 /) mm^(3 ) (SD ± 3,64) dan sesudah kemoterapi 8,61 × 〖10〗^(3 /) mm^3 (SD ± 4,24), rata rata eosinofil sebelum kemoterapi 1,34% (SD ± 1,31) dan sesudah kemoterapi 0,18% (SD ± 1,01), rata rata basofil sebelum kemoterapi 0,48%(SD ± 0,50) dan sesudah kemoterapi 0,05%(SD ± 0,21), rata-rata neutrofil batang sebelum kemoterapi 0,12% (SD ± 0,33) dan sesudah kemoterapi 0,02% (SD ±0,21%), rata-rata neutrofil segmen sebelum kemoterapi 55,43% (SD ±15,33). dan sesudah kemoterapi 82,68% (SD ± 9,54),rata-rata ANC sebelum kemoterapi 4,150 × 〖10〗^(3 /) mm^3 (SD ± 2,702) dan sesudah kemoterapi 7,735× 〖10〗^(3 /) mm^3 (SD ± 3,385), rata-rata limfosit sebelum kemoterapi 33,72% (SD ±12,53%) dan sesudah kemoterapi 15,22% (SD ± 8,25%) rata-rata monosit sebelum kemoterapi 8,91% (SD ± 4,26%) dan sesudah kemoterapi 1,86 (SD ± 2,12). Pada penelitian ini terdapat adanya penurunan nilai rata-rata pada variabel eosinofil, basofil, neutrofil batang dan limfosit. Sedangkan pada variabel hemoglobin, trombosit, leukosit,neutrofil segmen, dan ANC mengalami peningkatan rata rata setelah kemoterapi.

Kata Kunci : Kanker Ovarium, Profil Hematologi, Kemoterapi.

Ovarian cancer is the third most common gynecological cancer in Indonesia. The incidence of ovarian cancer in Indonesia in 2020 was 14,896 new cases and 9,000 deaths. Chemotherapy aims to stop the growth of cancer cells. Chemotherapy drugs for ovarian cancer have the side effect of myelosuppression which suppresses progenitor cells in the bone marrow which results in an impact on the hematological profile. The aim of this study was to determine the hematological profile of ovarian cancer patients before and after the 2nd cycle of chemotherapy at RSUDZA Banda Aceh in 2022. This retrospective descriptive study used medical record data in the period January - December 2022. Data were analyzed using frequency distribution tables and t tests paired before and after chemotherapy. There were 65 medical record data that met the inclusion and exclusion criteria in this study. The results of this study showed that the majority were aged 46-55 years (41.5%), the most chemotherapy regimens were carboplatin and Fancopac (78.5%), the most common histopathological types were Papillary Adenocarcinoma (47.7%), average hemoglobin before chemotherapy 9.90 (SD ± 3.71) and after chemotherapy 10.75 g/dL (SD ± 2.70), average platelet before chemotherapy 308,37 × 〖10〗^3 〖mm〗^(3 ) (SD ± 147,23 ) and after chemotherapy 311,48 × 〖10〗^(3 /) 〖mm〗^3(SD ± 109,96), average leukocytes before chemotherapy kemoterapi 6,18 × 〖10〗^(3 /) 〖mm〗^(3 ) (SD ± 3,64) and after chemotherapy 8,61 × 〖10〗^(3 /) 〖mm〗^3 (SD ± 4,24), mean mean eosinophils before chemotherapy 1.34% (SD ± 1.31) and after chemotherapy 0.18% (SD ± 1.01), mean basophils before chemotherapy 0.48% (SD ± 0.50) and after chemotherapy 0 .05%(SD ± 0.21), average stem neutrophils before chemotherapy 0.12% (SD ± 0.33) and after chemotherapy 0.02% (SD ± 0.21%), average segment neutrophils before chemotherapy 55.43% (SD ±15.33). and after chemotherapy 82.68% (SD ± 9.54), mean ANC before chemotherapy 4,150 × 〖10〗^(3 /) 〖mm〗^3 (SD ± 2,702) and after chemotherapy7,735× 〖10〗^(3 /) 〖mm〗^3 (SD ± 3,385) , average lymphocytes before chemotherapy 33.72% (SD ± 12.53%) and after chemotherapy 15.22% (SD ± 8.25%) average monocytes before chemotherapy 8.91% (SD ± 4.26%) and after chemotherapy 1.86 (SD ± 2.12). In this study, there was a decrease in the average values for the variables eosinophils, basophils, rod neutrophils and lymphocytes. Meanwhile, the variables hemoglobin, platelets, leukocytes, neutrophil segment, and ANC experienced an increase in average after chemotherapy. Keywords: Ovarian Cancer, Hematology Profile, Chemotherapy.